Press Release For The Medicinal Product For Human Use «Adempas»

Original Language Title: Comunicato relativo al medicinale per uso umano «Adempas»

Read the untranslated law here:

Please be informed that the Committee, at its meeting on 5-6 prices and reimbursement November 2014 has delivered a negative opinion on the new listings for the following indication: pulmonary arterial hypertension (pulmonary arterial hypertension, PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, it is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with CF who functional class II to III to improve the capacity of exercise. The efficacy has been shown in patients with hereditary or idiopathic PAH or PAH associated with connective tissue disorders.